Phoenix AZ 多发性骨髓瘤临床试验
16项针对 多发性骨髓瘤的研究正在 Phoenix及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic Arizona /ID# 251405, Phoenix
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
招募中3 期
- Mayo Clinic Phoenix, Mayo Clinic Building, Phoenix
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
招募中4 期
- Mayo Clinic Cancer Center-Scottsdale, Phoenix
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Mayo Clinic Phoenix, Phoenix
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
招募中2 期
- Mayo Clinic - Arizona, Phoenix
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic Hospital in Arizona, Phoenix
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
招募中3 期
- Research Site, Phoenix
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Phoenix
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Mayo Clinic 1, Phoenix
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Cancer Treatment Centers of America-Phoenix, Phoenix
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic Arizona, Phoenix
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
招募中3 期
- Cancer Center at Saint Joseph's, Phoenix
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Phoenix
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- Mayo Clinic in Arizona - Phoenix, Phoenix
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
招募中3 期
- Cancer Center at Saint Joseph's, Phoenix
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
招募中3 期
- GSK Investigational Site, Phoenix
其他城市的 多发性骨髓瘤试验
- New York City, NY59 项研究
- Boston, MA45 项研究
- Atlanta, GA42 项研究
- Houston, TX39 项研究
- Durham, NC36 项研究
- Nashville, TN31 项研究
- Denver, CO26 项研究
- St. Louis, MO26 项研究
- Rochester, MN25 项研究
- Columbus, OH25 项研究
- Chicago, IL24 项研究
- Milwaukee, WI23 项研究
Phoenix的其他研究
- 乳腺癌25 项研究
- 结直肠癌24 项研究
- 非小细胞肺癌21 项研究
- 转移性癌症19 项研究
- 肥胖症19 项研究
- 胰腺癌18 项研究
- 癌症（所有类型）17 项研究
- 心血管疾病16 项研究
- 前列腺癌16 项研究
- 心力衰竭16 项研究
- 阿尔茨海默病15 项研究
- 急性髓系白血病13 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。